vorinostat has been researched along with Reperfusion Injury in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Reperfusion Injury: Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Wang, J | 1 |
Deng, M | 1 |
Wu, H | 1 |
Wang, M | 1 |
Gong, J | 1 |
Bai, H | 1 |
Wu, Y | 1 |
Pan, J | 1 |
Chen, Y | 1 |
Li, S | 1 |
1 other study available for vorinostat and Reperfusion Injury
Article | Year |
---|---|
Suberoylanilide hydroxamic acid alleviates orthotopic liver transplantation‑induced hepatic ischemia‑reperfusion injury by regulating the AKT/GSK3β/NF‑κB and AKT/mTOR pathways in rat Kupffer cells.
Topics: Animals; Autophagy; Glycogen Synthase Kinase 3 beta; Kupffer Cells; Liver; Liver Diseases; Liver Tra | 2020 |